NASDAQ:ESPR - Esperion Therapeutics Stock Price, Forecast & News

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics Inc (NASDAQ:ESPR) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($2.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.95) by $0.42. The biopharmaceutical company earned $0.98 million during the quarter, compared to analysts' expectations of $0.99 million. During the same period in the previous year, the business posted ($1.86) EPS. View Esperion Therapeutics' Earnings History.

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Esperion Therapeutics.

9 brokerages have issued twelve-month price targets for Esperion Therapeutics' stock. Their forecasts range from $45.00 to $90.00. On average, they expect Esperion Therapeutics' share price to reach $65.00 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.

Press coverage about ESPR stock has been trending very negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Esperion Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Esperion Therapeutics.

Esperion Therapeutics saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,960,000 shares, a decline of 6.8% from the December 15th total of 5,320,000 shares. Based on an average trading volume of 442,600 shares, the short-interest ratio is presently 11.2 days. Approximately 19.5% of the shares of the company are short sold. View Esperion Therapeutics' Current Options Chain.

Some companies that are related to Esperion Therapeutics include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), Ship Finance International (SFL), NVIDIA (NVDA), Micron Technology (MU), NXP Semiconductors (NXPI), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN) and Boeing (BA).

Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (2.42%), California Public Employees Retirement System (0.21%), Virginia Retirement Systems ET AL (0.03%), Assenagon Asset Management S.A. (0.02%), Tocqueville Asset Management L.P. (0.02%) and Steward Partners Investment Advisory LLC (0.01%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL and Steward Partners Investment Advisory LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo, Richard Bartram and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.

ESPR stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Assenagon Asset Management S.A., Tocqueville Asset Management L.P. and Rhenman & Partners Asset Management AB. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ESPR stock can currently be purchased for approximately $54.01.

Esperion Therapeutics has a market capitalization of $1.48 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.View Additional Information About Esperion Therapeutics.

The official website for Esperion Therapeutics is http://www.esperion.com/.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]